Literature DB >> 22437990

Tissue temperature feedback control of power: the key to successful ablation.

David K Swanson1, Wendel J Smith, Tamer Ibrahim, Andrew S Wechsler.   

Abstract

Multiple ablation technologies are used to treat atrial fibrillation during cardiac operations. All such ablation technologies use locally induced temperature extremes (>50°C or <-20°C) to kill tissue and create a lesion pattern in the atria which blocks activation pathways that initiate and sustain atrial fibrillation. The technologies used to heat tissue have included radiofrequency (RF), microwave, high-intensity focused ultrasound, and infrared laser. RF accounts for more than 95% of the heating-based ablation technology used by cardiac surgeons. Energy delivery with RF is easier to control than with some other technologies, the heating produced by the energy source is well understood, and manufacturing costs are not excessive. Whichever heating technology is used, control of energy delivery is required to ensure both safe and effective heating of the targeted tissue. All targeted tissue needs to be heated above 50°C to achieve cell death. However, the targeted tissue should not be heated above 100°C, as this can cause perforation due to a steam pop. In addition, adjacent noncardiac tissues must not be damaged during the ablation procedure. The best method to achieve this control uses direct measurement of tissue temperature, because the tissue temperature defines both the safe and effective limits for the ablative process.

Entities:  

Year:  2011        PMID: 22437990     DOI: 10.1097/IMI.0b013e31822b4d22

Source DB:  PubMed          Journal:  Innovations (Phila)        ISSN: 1556-9845


  1 in total

1.  Performance of a novel bipolar/monopolar radiofrequency ablation device on the beating heart in an acute porcine model.

Authors:  Lindsey L Saint; Christopher P Lawrance; Shoichi Okada; Toshinobu Kazui; Jason O Robertson; Richard B Schuessler; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2013 Jul-Aug
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.